Researchers from the Institute for Molecular Bioscience have been awarded international funding to combat an expected escalation of skin cancer cases in US troops who served in Iraq and Afghanistan.
2022
M14TIL: Tumor-Infiltrating Lymphocytes for Patients With Advanced Melanoma
A novel treatment strategy with personalized cell therapy significantly improved progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to results from the phase III M14TIL trial reported by John Haanen, MD, PhD, and colleagues at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA3).
COLUMBUS Trial 5-Year Update: Encorafenib/Binimetinib vs Vemurafenib or Encorafenib in Advanced BRAF V600–Mutant Melanoma
In a 5-year update of part 1 of the phase III COLUMBUS trial reported in the Journal of Clinical Oncology, Dummer et al found a continued benefit of encorafenib plus binimetinib vs vemurafenib in patients with advanced BRAF V600–mutant melanoma. The trial supported the June 2018 approval of encorafenib plus binimetinib in this setting.
Melanomas are rising rapidly and older men in rural and regional Australia are most at risk
John Seccombe had regularly checked his skin and even had small cancers on his face removed, but nothing prepared him for the moment when the right side of his face went numb.